Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
On Drug-Distribution and Pharmacy Stocks
Vitaliy Katsenelson, CFA
Student of Life
These pharnacy stocks are good businesses. In general they have solid balance sheets, above-average returns on capital, and they generate a lot of cash, which is used to pay dividends and buy back stock.
But, these defensive features have not mattered much lately, as we are entering the 10th year of uninterrupted economic expansion.
Accordingly, these companies are significantly undervalued. How under valued? Let’s answer that question by examining two stocks in our portfolio in closer detail.
***
Prescription Pill Bottles
***
Here’s Why Drug-Distribution and Pharmacy Stocks are Bargains Now
***
***
Share this:
Filed under: Drugs and Pharma, Investing | Tagged: By Vitaliy Katsenelson CFA, Drug-Distribution Stocks, Drugs, PBMs, Pharmacy Stocks |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
PHARMA
Traditional pharmacies are a headache (oh, the irony). That’s why NowRx is redefining pharmacy by offering free, same-day prescription delivery and amazing customer service—and their potential is growing quickly.
They’ve already raised over $5M in investments in less than 3 weeks and with NowRx’s new telehealth product growing 73% month over month since inception the time to invest has never been better.
NowRx is rebuilding healthcare for convenience and affordability, and after the Last Year (cue thunder and lightning SFX) it’s clear how valuable that is as the company generated over $13.4M in revenue (up 90% annually) and is on pace to hit over $22M this year!
George
LikeLike